Pediatric Intensive Care Unit. St. Mary's Hospital, Imperial College Healthcare National Health Service Trust, London, United Kingdom.
Clinical Research Department, London School of Hygiene and Tropical Medicine, London, United Kingdom.
Pediatr Crit Care Med. 2023 Jan 1;24(1):e54-e59. doi: 10.1097/PCC.0000000000003093. Epub 2022 Oct 14.
Designing randomized trials to determine utility, dose, and timing of steroid administration in the management of critically unwell children may be difficult owing to a high proportion of patients who receive steroid as part of current care. We aimed to describe steroid use among all patients on two general PICUs.
Retrospective observational study using a multilevel logistic regression model.
Two tertiary, general mixed medical and surgical PICUs.
All admissions between 2016 and 2019. All parenteral or enteral steroid prescriptions were identified, and steroid type, frequency, timing, and peak daily doses were recorded. The outcome measure was mortality prior to PICU discharge.
None.
There were 5,483 admissions during the study period, and 1,804 (33%) of these involved prescription of at least one steroid. Among patients prescribed steroids, the median peak daily dose when steroids were prescribed was 2.4 mg/kg/d prednisolone equivalent (interquartile range, 1.6-3.6), and the median time to peak steroid doses was 2 days (1-5 d). Administration of steroid was associated with increased risk-adjusted mortality odds ratio (OR) of 1.37 (95% CI, 1.04-1.79). Steroids were prescribed in 42.3% of admissions, in which the child did not survive to PICU discharge. Among children who were prescribed steroids, use of hydrocortisone (OR, 6.75; 95% CI, 3.79-12.27) and methylprednisolone (OR, 7.85; 95% CI, 4.21-14.56), or starting steroids later than 2 days after PICU admission were associated with an increased mortality (OR, 1.93; 95% CI, 1.15-3.25).
Steroids are widely used in pediatric critical illness and nonsurvival associated with increased frequency of use. This association appears to be related to steroid class and timing of dose, both likely to reflect indication for steroid prescription. Prospective trials are required to estimate these complex risks and benefits, and study design will need to consider these patterns.
由于很大一部分患者在接受目前的治疗时都接受了类固醇治疗,因此设计旨在确定类固醇给药在危重症儿童管理中的效用、剂量和时间的随机试验可能具有挑战性。我们旨在描述两个综合儿科重症监护病房(PICU)中所有患者的类固醇使用情况。
使用多级逻辑回归模型的回顾性观察性研究。
两个三级综合内科和外科混合 PICU。
2016 年至 2019 年期间所有入院患者。所有静脉或肠内类固醇处方均被识别,记录了类固醇类型、频率、时间和峰值日剂量。主要结局指标为 PICU 出院前的死亡率。
无。
在研究期间共有 5483 例住院,其中 1804 例(33%)至少开具了一种类固醇处方。在开具类固醇的患者中,开具类固醇时的中位峰值日剂量为 2.4mg/kg/d 泼尼松龙当量(中位数,1.6-3.6),中位达到峰值类固醇剂量的时间为 2 天(1-5 天)。调整风险后的类固醇给药与死亡率比值比(OR)增加相关,为 1.37(95%可信区间,1.04-1.79)。42.3%的住院患者开具了类固醇,其中患儿未存活至 PICU 出院。在开具类固醇的患儿中,使用氢化可的松(OR,6.75;95%可信区间,3.79-12.27)和甲泼尼龙(OR,7.85;95%可信区间,4.21-14.56)或在 PICU 入院后 2 天以上开始使用类固醇与死亡率增加相关(OR,1.93;95%可信区间,1.15-3.25)。
类固醇在儿科危重症中广泛使用,与使用频率增加相关的存活率降低。这种关联似乎与类固醇类别和剂量时间有关,这两者都可能反映了类固醇处方的指征。需要前瞻性试验来估计这些复杂的风险和益处,并且研究设计需要考虑这些模式。